《大行报告》摩通上调创科(00669.HK)目标价至136元 予「增持」评级
摩根大通发表报告,重予创科(00669.HK)「增持」评级,按现金流折现率作估值,对其目标价由108港元上调至136港元。该行看好全球电动工具行业前景,并指公司在美国业务布局良好。
该行相信凭藉创新能力及供应链管理能力,创科未来表现可优於同业,支持其进一步增长;该行看好创科良好执行力及强劲的产品,料创科估值可达明年预测市盈率34倍,较全球同业预测市盈率28倍有估值溢价。
摩通料创科於2020年至2022年每股经调整盈利预测分别为0.39美元、0.47美元及0.57美元。(wl/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.